VP16-213, cisplatinum, and adriamycin salvage therapy of refractory and/or recurrent nonseminomatous germ cell neoplasms

J. Mortimer, R. M. Bukowski, J. Montie, J. S. Hewlett, Robert B Livingston

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Eleven patients with recurrent and/or resistant nonseminomatous germinal cell neoplasms refractory to conventional chemotherapy were treated with the combination VP16-213, cis-diamminedichloroplatinum, and adriamycin. One complete response, four partial responses which at surgery were benign teratomas, and six partial responses have been observed. Four patients are prolonged survivors (>18 months). The possibility that this regimen may offer true salvage for refractory patients exists. Incorporation of VP16-213 into initial treatment regimens for germinal cell neoplasms is warranted.

Original languageEnglish (US)
Pages (from-to)215-218
Number of pages4
JournalCancer Chemotherapy and Pharmacology
Volume7
Issue number2-3
DOIs
StatePublished - 1982
Externally publishedYes

Fingerprint

Salvaging
Salvage Therapy
Germ Cell and Embryonal Neoplasms
Refractory materials
Doxorubicin
Cells
Chemotherapy
Surgery
Cisplatin
Teratoma
Survivors
Neoplasms
Drug Therapy
Therapeutics

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Pharmacology

Cite this

VP16-213, cisplatinum, and adriamycin salvage therapy of refractory and/or recurrent nonseminomatous germ cell neoplasms. / Mortimer, J.; Bukowski, R. M.; Montie, J.; Hewlett, J. S.; Livingston, Robert B.

In: Cancer Chemotherapy and Pharmacology, Vol. 7, No. 2-3, 1982, p. 215-218.

Research output: Contribution to journalArticle

@article{1fc6ce2abfb840008a45113816fd9a8a,
title = "VP16-213, cisplatinum, and adriamycin salvage therapy of refractory and/or recurrent nonseminomatous germ cell neoplasms",
abstract = "Eleven patients with recurrent and/or resistant nonseminomatous germinal cell neoplasms refractory to conventional chemotherapy were treated with the combination VP16-213, cis-diamminedichloroplatinum, and adriamycin. One complete response, four partial responses which at surgery were benign teratomas, and six partial responses have been observed. Four patients are prolonged survivors (>18 months). The possibility that this regimen may offer true salvage for refractory patients exists. Incorporation of VP16-213 into initial treatment regimens for germinal cell neoplasms is warranted.",
author = "J. Mortimer and Bukowski, {R. M.} and J. Montie and Hewlett, {J. S.} and Livingston, {Robert B}",
year = "1982",
doi = "10.1007/BF00254553",
language = "English (US)",
volume = "7",
pages = "215--218",
journal = "Cancer Chemotherapy and Pharmacology",
issn = "0344-5704",
publisher = "Springer Verlag",
number = "2-3",

}

TY - JOUR

T1 - VP16-213, cisplatinum, and adriamycin salvage therapy of refractory and/or recurrent nonseminomatous germ cell neoplasms

AU - Mortimer, J.

AU - Bukowski, R. M.

AU - Montie, J.

AU - Hewlett, J. S.

AU - Livingston, Robert B

PY - 1982

Y1 - 1982

N2 - Eleven patients with recurrent and/or resistant nonseminomatous germinal cell neoplasms refractory to conventional chemotherapy were treated with the combination VP16-213, cis-diamminedichloroplatinum, and adriamycin. One complete response, four partial responses which at surgery were benign teratomas, and six partial responses have been observed. Four patients are prolonged survivors (>18 months). The possibility that this regimen may offer true salvage for refractory patients exists. Incorporation of VP16-213 into initial treatment regimens for germinal cell neoplasms is warranted.

AB - Eleven patients with recurrent and/or resistant nonseminomatous germinal cell neoplasms refractory to conventional chemotherapy were treated with the combination VP16-213, cis-diamminedichloroplatinum, and adriamycin. One complete response, four partial responses which at surgery were benign teratomas, and six partial responses have been observed. Four patients are prolonged survivors (>18 months). The possibility that this regimen may offer true salvage for refractory patients exists. Incorporation of VP16-213 into initial treatment regimens for germinal cell neoplasms is warranted.

UR - http://www.scopus.com/inward/record.url?scp=0020058918&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0020058918&partnerID=8YFLogxK

U2 - 10.1007/BF00254553

DO - 10.1007/BF00254553

M3 - Article

C2 - 6282486

AN - SCOPUS:0020058918

VL - 7

SP - 215

EP - 218

JO - Cancer Chemotherapy and Pharmacology

JF - Cancer Chemotherapy and Pharmacology

SN - 0344-5704

IS - 2-3

ER -